Literature DB >> 15034540

Incidence and clinical complications of vancomycin-resistant enterococcus in pediatric stem cell transplant patients.

A C Tsiatis1, B Manes, C Calder, D Billheimer, K S Wilkerson, H Frangoul.   

Abstract

Vancomycin-resistant enterococcus (VRE) are increasingly important pathogens in stem cell transplant (SCT). In all, 61 pediatric SCT patients had surveillance stool cultures for VRE between July 1999 and November 2002. When VRE was identified, the patients were placed on strict contact isolation. VRE was detected in 15 patients (24.6%). The median age was 3.6 years (range 0.6-18.5 years). Of the 15, 13 (87%) received an allogeneic transplant (six unrelated and seven related). Five of the 15 (33%) colonized patients developed VRE bacteremia. The bacteremia resolved in all five patients after therapy with quinupristin/dalfopristin; three patients required central line removal. Four patients died (38-153 days) post-SCT due to relapse or transplant complication not related to VRE. Of the 11 surviving patients, seven cleared the colonization at a median of 144 days (range 61-198 days) postcolonization. Four patients remain colonized at 68-702 days after the first positive culture. Intestinal colonization with VRE occurred commonly in pediatric SCT patients. Although the morbidity from VRE was not substantial, transplant patients were colonized for prolonged periods. Our results indicate that surveillance for VRE is an effective way to identify colonized patients and may lead to a decrease in transmission to other patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034540     DOI: 10.1038/sj.bmt.1704462

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  The intestinal microbiota and susceptibility to infection in immunocompromised patients.

Authors:  Ying Taur; Eric G Pamer
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

2.  The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.

Authors:  J R de la Court; A H W Bruns; A H E Roukens; I O Baas; K van Steeg; M L Toren-Wielema; M Tersmette; N M A Blijlevens; R A G Huis In 't Veld; T F W Wolfs; W J E Tissing; Y Kyuchukova; J Heijmans
Journal:  Infect Dis Ther       Date:  2022-10-14

3.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

4.  Colonization Rate and Risk Factors of Vancomycin-Resistant Enterococci among Patients Received Hematopoietic Stem Cell Transplantation in Shiraz, Southern Iran.

Authors:  M Kaveh; A Bazargani; M Ramzi; H Sedigh Ebrahim-Saraie; H Heidari
Journal:  Int J Organ Transplant Med       Date:  2016-11-01

5.  Colonization With Vancomycin-Resistant Enterococci and Risk for Bloodstream Infection Among Patients With Malignancy: A Systematic Review and Meta-Analysis.

Authors:  Michail Alevizakos; Apostolos Gaitanidis; Dimitrios Nasioudis; Katerina Tori; Myrto Eleni Flokas; Eleftherios Mylonakis
Journal:  Open Forum Infect Dis       Date:  2016-12-07       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.